and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines ...

The quote below is from a Wall Street Journal interview ... Unfortunately, investors seeking shelter in healthcare stocks for dividend growth and capital gains have been unable to outperform ...

and the looming loss of exclusivity for blockbuster cancer drug Keytruda. We recently compiled a list of the 10 Best Dow Jones Dividend Stocks According to Wall Street Analysts. In this article, we ...

We recently published a list of 10 Small–Cap Stocks Insiders Are Selling Recently ... pevedotin plus Merck & Co Inc’s (NYSE:MRK) Keytruda (pembrolizumab) in previously untreated (first ...

NEW YORK, December 12, 2024--Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared an increase in the quarterly cash dividend on the company’s common stock to $0.43 for ...

Deutsche Bank analyst James Shin downgraded Merck (MRK) to Hold from Buy with a price target of $105, down from $128. The firm believes the ...

The agreement, which also includes a team of biotech executives, will see Bluebird Bio’s stockholders receive $3.00 per share ...

MRK’s Study on Keytruda Lenvima Combo Misses OS Goal Merck ... Here’s how the eight major stocks performed in the previous five trading sessions. Image Source: Zacks Investment Research ...

Shares of Acelyrin climbed after the company said it has received an unsolicited indication of interest from Concentra Biosciences for an acquisition at $3 a share. The stock was up 14% at $2.48 in ...

Pyxis Oncology announces Phase 1/2 trials for PYX-201, combining it with KEYTRUDA® to treat advanced solid tumors. Pyxis Oncology, Inc. has announced the initiation of two significant clinical ...